Jeryl L. Hilleman, Director at NovoCure Ltd (NVCR), sold 407 shares at $69.61 ($28K) on 2022-06-10, disclosed to the SEC on 2022-06-16.
Scheduled sale ($28k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| SIBN | SELL | 2023-06-20 | $178K | — | Filing → |
| SIBN | SELL | 2022-06-14 | $27K | — | Filing → |
| SIBN | SELL | 2021-06-28 | $148K | — | Filing → |